Current Report Filing (8-k)
August 03 2017 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): August 3, 2017
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-22705
|
|
33-0525145
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
12780 El Camino Real, San Diego, California
|
|
92130
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858) 617-7600
N/A
(Former name or
former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
|
RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
|
On August 3, 2017, Neurocrine
Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2017. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on
Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current
Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release dated August 3, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
|
|
|
Dated: August 3, 2017
|
|
|
|
NEUROCRINE BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
/s/ David-Alexandre C. Gros
|
|
|
|
|
David-Alexandre C. Gros
|
|
|
|
|
President, Chief Operating Officer and
interim Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release dated August 3, 2017
|
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Apr 2024 to May 2024
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From May 2023 to May 2024